Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Timothy Sheahan and Ralph Baric.
Connection Strength

8.460
  1. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 04 29; 12(541).
    View in: PubMed
    Score: 0.876
  2. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 01 10; 11(1):222.
    View in: PubMed
    Score: 0.861
  3. Is regulation preventing the development of therapeutics that may prevent future coronavirus pandemics? Future Virol. 2018 Mar; 13(3):143-146.
    View in: PubMed
    Score: 0.756
  4. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017 06 28; 9(396).
    View in: PubMed
    Score: 0.722
  5. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J Virol. 2011 Jan; 85(1):217-30.
    View in: PubMed
    Score: 0.455
  6. Pathways of cross-species transmission of synthetically reconstructed zoonotic severe acute respiratory syndrome coronavirus. J Virol. 2008 Sep; 82(17):8721-32.
    View in: PubMed
    Score: 0.387
  7. Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion in human airway epithelium. J Virol. 2008 Mar; 82(5):2274-85.
    View in: PubMed
    Score: 0.373
  8. Resurrection of an "extinct" SARS-CoV isolate GD03 from late 2003. Adv Exp Med Biol. 2006; 581:547-50.
    View in: PubMed
    Score: 0.326
  9. Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. Cell Rep. 2021 07 27; 36(4):109450.
    View in: PubMed
    Score: 0.239
  10. Critical ACE2 Determinants of SARS-CoV-2 and Group 2B Coronavirus Infection and Replication. mBio. 2021 03 16; 12(2).
    View in: PubMed
    Score: 0.234
  11. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J Exp Med. 2021 03 01; 218(3).
    View in: PubMed
    Score: 0.233
  12. Publisher Correction: A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2021 Feb; 590(7844):E22.
    View in: PubMed
    Score: 0.232
  13. A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell. 2020 11 12; 183(4):1070-1085.e12.
    View in: PubMed
    Score: 0.226
  14. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020 10; 586(7830):560-566.
    View in: PubMed
    Score: 0.225
  15. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep. 2020 07 21; 32(3):107940.
    View in: PubMed
    Score: 0.223
  16. Increasing the translation of mouse models of MERS coronavirus pathogenesis through kinetic hematological analysis. PLoS One. 2019; 14(7):e0220126.
    View in: PubMed
    Score: 0.208
  17. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019 09; 169:104541.
    View in: PubMed
    Score: 0.207
  18. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio. 2018 10 09; 9(5).
    View in: PubMed
    Score: 0.197
  19. Conformational Occlusion of Blockade Antibody Epitopes, a Novel Mechanism of GII.4 Human Norovirus Immune Evasion. mSphere. 2018 Jan-Feb; 3(1).
    View in: PubMed
    Score: 0.188
  20. SARS-like WIV1-CoV poised for human emergence. Proc Natl Acad Sci U S A. 2016 Mar 15; 113(11):3048-53.
    View in: PubMed
    Score: 0.165
  21. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J Infect Dis. 2010 Mar 15; 201(6):946-55.
    View in: PubMed
    Score: 0.109
  22. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog. 2008 Dec; 4(12):e1000240.
    View in: PubMed
    Score: 0.100
  23. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J Virol. 2008 Apr; 82(7):3220-35.
    View in: PubMed
    Score: 0.094
  24. Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice. J Virol. 2007 Jul; 81(14):7410-23.
    View in: PubMed
    Score: 0.090
  25. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res. 2008 Apr; 133(1):45-62.
    View in: PubMed
    Score: 0.089
  26. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 2006 Dec; 3(12):e525.
    View in: PubMed
    Score: 0.087
  27. SARS coronavirus vaccine development. Adv Exp Med Biol. 2006; 581:553-60.
    View in: PubMed
    Score: 0.081
  28. Cryo-EM and antisense targeting of the 28-kDa frameshift stimulation element from the SARS-CoV-2 RNA genome. Nat Struct Mol Biol. 2021 09; 28(9):747-754.
    View in: PubMed
    Score: 0.060
  29. ß-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. J Infect Dis. 2021 08 02; 224(3):415-419.
    View in: PubMed
    Score: 0.060
  30. Genomic RNA Elements Drive Phase Separation of the SARS-CoV-2 Nucleocapsid. Mol Cell. 2020 12 17; 80(6):1078-1091.e6.
    View in: PubMed
    Score: 0.057
  31. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell. 2020 11 25; 183(5):1367-1382.e17.
    View in: PubMed
    Score: 0.057
  32. Small-Molecule Antiviral ß-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. J Virol. 2019 12 15; 93(24).
    View in: PubMed
    Score: 0.053
  33. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018 03 06; 9(2).
    View in: PubMed
    Score: 0.047
  34. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol. 2009 Jul; 83(14):7062-74.
    View in: PubMed
    Score: 0.026
  35. Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice. Proc Natl Acad Sci U S A. 2008 Dec 16; 105(50):19944-9.
    View in: PubMed
    Score: 0.025
  36. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J Virol. 2008 Aug; 82(15):7721-4.
    View in: PubMed
    Score: 0.024
  37. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A. 2007 Jul 17; 104(29):12123-8.
    View in: PubMed
    Score: 0.023
  38. Animal models and vaccines for SARS-CoV infection. Virus Res. 2008 Apr; 133(1):20-32.
    View in: PubMed
    Score: 0.022
  39. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 2007 Jan; 3(1):e5.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.